К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 7 min

Soft tissue sarcoma: when chemotherapy is needed and when surgery is enough

Soft tissue sarcomas: why biopsy before surgery matters, the role of radiotherapy, when chemotherapy is justified, doxorubicin, trabectedin and other options in advanced disease, lung metastases.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Soft tissue sarcomas are rare tumours that arise from fat, muscle, connective and other tissues. There are dozens of different types, and it is the subtype that most often decides whether chemotherapy will help. Treatment requires experience, because a mistake at the first step (a poor biopsy or a "simple" removal) is hard to correct later.

In this article I explain how correct diagnosis begins, how surgery and radiotherapy are combined, when chemotherapy is discussed, which drugs are used in advanced disease and what to do about lung metastases.

Why it is better to start treatment at a specialised centre

Sarcomas are rare, so an ordinary surgeon or oncologist may not have much experience. It is recommended that diagnosis and the first operation take place at a centre that treats sarcomas regularly and that the plan is discussed at a tumour board with a surgical oncologist, radiation oncologist, medical oncologist, radiologist and pathologist.

Signs that should make you think of sarcoma and not delay investigation:

  • a firm mass in the soft tissues that is growing;
  • size over 5 cm or location beneath the fascia (deep);
  • a mass that hurts or enlarges quickly;
  • a mass that "was removed and grew back".

Diagnosis: what to do before surgery

  1. MRI of the tumour area (or CT depending on the site): assesses size and relation to structures.
  2. Core needle biopsy (a core of tissue taken with a needle), not "cutting off a piece during surgery". The biopsy is planned so the needle track can later be removed together with the tumour.
  3. Pathology with immunohistochemistry and, if needed, molecular tests (for example looking for translocations). The exact subtype and grade determine tactics (what grade means).
  4. CT of the chest: the lungs are the most common site of metastases. For some subtypes CT or MRI of other areas is added.

If the tumour has already been removed without prior diagnosis (so-called "unplanned excision"), the specimen and slides should be shown at a specialised centre. A repeat operation (wide re-excision) in the scar area is often needed to remove remaining cells. Slide review: pathology slide review.

Treatment of localised sarcoma

Surgery is the basis of treatment. The goal is to remove the tumour in one piece with a margin of healthy tissue so that no tumour cells remain at the edges (resection margin). Modern surgery more often saves the limb, and amputation is needed less often.

Radiotherapy complements surgery for large (over 5 cm), deep and high-grade tumours. It is given before surgery (about 5 weeks; it usually reduces volume better) or after. The choice depends on tumour location and risk of complications (for example wound healing).

Retroperitoneal sarcomas need a special approach: surgery at a centre with great experience, often with removal of neighbouring organs in one block. The role of radiotherapy and chemotherapy here is discussed individually.

When chemotherapy is discussed in localised disease

This is one of the most debated parts. Chemotherapy before or after surgery is considered not for everyone but for patients at high risk of recurrence: large (over 5 cm), deep, high-grade tumours of sensitive subtypes. Trial results are contradictory, and the benefit depends on subtype and the patient's condition, so the decision is made by a tumour board after weighing pros and cons.

A typical regimen if chemotherapy is chosen: doxorubicin with ifosfamide (sometimes with epirubicin) for several cycles. It is important to know that many subtypes (for example myxoid liposarcoma, synovial sarcoma) are more sensitive, while others (for example clear cell sarcoma and some low-grade types) respond less well. Reference on drugs: chemotherapy regimens, cardiotoxicity.

Advanced and metastatic sarcoma

When the disease is beyond the reach of surgery, treatment is systemic. Its goal is to keep the disease under control and preserve quality of life.

Line What is used
First Doxorubicin (more often alone). When the tumour needs to shrink quickly, doxorubicin with ifosfamide. In leiomyosarcoma, doxorubicin with dacarbazine in some situations
Next Gemcitabine with docetaxel (especially leiomyosarcoma, undifferentiated pleomorphic sarcoma), trabectedin (liposarcomas and leiomyosarcomas), eribulin (liposarcomas), pazopanib (other than liposarcomas)
Special subtypes Targeted drugs when there is a specific target (for example NTRK fusions, epithelioid sarcoma)

For tumours that resemble sarcoma but have separate treatment (for example GIST) the approach is quite different: GIST and imatinib. More on how targeted treatment works: targeted therapy.

Expectations should be discussed honestly. In advanced sarcoma chemotherapy more often slows growth than destroys the disease, and the effect is assessed by CT or MRI every 2–3 months (RECIST). If treatment is not working, it is important to move to the next line or a clinical trial in time (clinical trials, progression on treatment).

Lung metastases

The lungs are the main site of sarcoma metastases. With a small number of metastases and control of the main tumour, surgical removal, stereotactic radiotherapy or ablation is discussed. The decision depends on the number and size of metastases, how fast they appear and the patient's condition. More: lung metastases.

Side effects

Doxorubicin:

Ifosfamide:

  • bladder damage (so mesna and plenty of fluid are given);
  • neurological symptoms (confusion, drowsiness) in rare cases;
  • kidney damage.

Pazopanib: raised blood pressure, liver damage, diarrhoea, changes in hair colour.

Fertility

Some drugs affect fertility. If you plan to have children, discuss storing eggs, embryos or sperm before treatment begins: fertility preservation before chemotherapy.

Follow-up

After treatment, follow-up includes examination and MRI of the tumour area (sometimes ultrasound) and CT of the chest. In the first 2–3 years check-ups are more frequent, then less so. Recurrence is more common precisely in the first years.

What to ask your doctor

  • What is the exact subtype and grade? Were the slides reviewed in a reference laboratory?
  • Was there a biopsy before surgery? Is a repeat operation needed?
  • Is radiotherapy needed and when: before or after surgery?
  • Is chemotherapy suitable for me or is surgery enough?
  • If I need chemotherapy, which regimen and on what basis?
  • Is there a specific molecular target?
  • Which centre treats sarcomas regularly?

When to seek urgent help

  • temperature of 38 °C or above;
  • rapid growth of the mass, severe pain, numbness or weakness in a limb;
  • shortness of breath, chest pain, coughing up blood;
  • swelling and pain in one leg (see thrombosis in cancer);
  • shortness of breath, swelling and fast heartbeat on doxorubicin.

Can I get a second opinion

Yes, and in sarcoma I consider it almost an obligatory step. Reasons: the tumour was removed without prior biopsy, the subtype was set uncertainly, amputation is offered, chemotherapy was given without discussing options or the disease has returned. Prepare the pathology (and slides, blocks), MRI or CT with discs and summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: sarcomas.

Sources

  1. Soft Tissue Sarcoma Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.